Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia

Bibliography

• Bartram CR, de Klein A, Hagemeijer A, Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Deininger M, O'Brien SG, Guilhot F, International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114: abstract 1126
   Web of Science ®Google Scholar
• Hochhaus A, O'Brien SG, Guilhot F, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on chronic myeloid leukemia. Clin Cancer Res 2006;12:7374-9
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nager B, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25
   PubMed Web of Science ®Google Scholar
• Ernst T, Erben P, Muller MC, Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186-92
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53-5
   PubMed Web of Science ®Google Scholar
• Modugno M, Casale E, Soncini C, Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67:7987-90
   PubMed Web of Science ®Google Scholar
• Muller MC, Cortes JE, Kim DW, Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-53
   PubMed Web of Science ®Google Scholar
• Tasigna (nilotinib) [Package insert]. East Hanover, NJ: Novartis; 2010
   Google Scholar
• Weisberg E, Manley PW, Breitenstein W, Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, AMN107 (nilotinib): a novel and selective inhibitor Bcr-Abl. Br J Cancer 2006;7:129-41
   Google Scholar
• O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell 2005;7:1117-19
   Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relative imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5
   PubMed Web of Science ®Google Scholar
• Von Bubnoff N, Manley PW, Mestan J, Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108:1328-33
   PubMed Web of Science ®Google Scholar
• Weisberg E, Catley L, Wright RD, Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007;109:2112-20
   PubMed Web of Science ®Google Scholar
• Griffin JD, Weisberg EL. Simultaneous administration of AMN107 and imatinib in the treatment of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia. Blood 2005;106: abstract 694
   Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Ottmann OG, Giles F, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Bhalla K, Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood 2009;114: abstract 1129
   Google Scholar
• Hughes T, Saglio G, Branford S, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-10
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Giles F, Apperely J, Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24 month follow-up results of a phase 2 study. Haematologica 2009;94: abstract 0631
   PubMed Web of Science ®Google Scholar
• Giles FJ, Kantarjian H, le Coutre PD, Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. J Clin Oncol 2010;28: abstract 6510
   Web of Science ®Google Scholar
• Giles F, Kantarjian HM, le Coutre P, Nilotinib induces rapid and durable responses with 24-month minimum follow-up in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis (CML-BC). Haematologica 2010;95: abstract 1138
   Web of Science ®Google Scholar
• Nicolini FE, Kim DW, Ceglarek B, Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CM) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study. Blood 2009;114: abstract 2201
   PubMed Web of Science ®Google Scholar
• Le Coutre PD, Turkina A, Kim DW, Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study. Blood 2009;114: abstract 3286
   Web of Science ®Google Scholar
• Cortes JE, Jones D, O'Brien S, Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-7
   PubMed Web of Science ®Google Scholar
• Rosti G, Palandri F, Castagnetti F, Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009;114:4933-8
   PubMed Web of Science ®Google Scholar
• O'Dwyer M, Kent E, Parker M, Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 Phase 2 study. Blood 2009;114: abstract 3294
   Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;262:2251-9
   Web of Science ®Google Scholar
• Guilhot F, Mahon FX, Guilhot J, Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML group (FI LMC). Blood 2008;112: abstract 183
   Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Branford S, Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: rational for combination tyrosine kinase inhibitor therapy. Blood 2005;106: abstract 1093
   Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21:1267-75
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yin OQP, Sethuraman V, Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010;87:197-203
   PubMed Web of Science ®Google Scholar
• Yin OPQ, Gallagher N, Li A, Effect of grapefruit juice on the pharmacokinetics of nilotinib in health participants. J Clin Pharmacol 2010;50:188-94
   PubMed Web of Science ®Google Scholar
• Tanaka C. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in health participants. J Clin Pharmacol 2010. [Epub 11 August 2010] doi: 10.1177/0091270010367428
   Google Scholar
• Yin OQ, Gallagher N, Fischer D, Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010;50:960-7
   PubMed Web of Science ®Google Scholar